Clinical trial
Phase I Study of T Cells Expressing an Anti-CD19 and Anti-CD20 Bispecific Chimeric Receptor in Patients With B Cell Malignancies
NCT03271515 is registered in ClinicalTrials.gov with Beijing Doing Biomedical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study of T Cells Expressing an Anti-CD19 and Anti-CD20 Bispecific Chimeric Receptor in Patients With B Cell Malignancies
- Lead sponsor
- Beijing Doing Biomedical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- March 1, 2021
- Completion date
- March 1, 2023
- Enrollment
- 20 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.